Historical Valuation
MDxHealth SA (MDXH) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.31 is considered Undervalued compared with the five-year average of -4.58. The fair price of MDxHealth SA (MDXH) is between 51.37 to 55.01 according to relative valuation methord. Compared to the current price of 3.27 USD , MDxHealth SA is Undervalued By 93.63%.
Relative Value
Fair Zone
51.37-55.01
Current Price：3.27
93.63%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
MDxHealth SA (MDXH) has a current Price-to-Book (P/B) ratio of -20.78. Compared to its 3-year average P/B ratio of -27.96 , the current P/B ratio is approximately -25.66% higher. Relative to its 5-year average P/B ratio of -26.20, the current P/B ratio is about -20.68% higher. MDxHealth SA (MDXH) has a Forward Free Cash Flow (FCF) yield of approximately -4.11%. Compared to its 3-year average FCF yield of -453.78%, the current FCF yield is approximately -99.09% lower. Relative to its 5-year average FCF yield of -99532.73% , the current FCF yield is about -100.00% lower.
P/B
Median3y
-27.96
Median5y
-26.20
FCF Yield
Median3y
-453.78
Median5y
-99532.73
Competitors Valuation Multiple
AI Analysis for MDXH
The average P/S ratio for MDXH competitors is 88.20, providing a benchmark for relative valuation. MDxHealth SA Corp (MDXH.O) exhibits a P/S ratio of 1.31, which is -98.52% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for MDXH
1Y
3Y
5Y
Market capitalization of MDXH increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of MDXH in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is MDXH currently overvalued or undervalued?
MDxHealth SA (MDXH) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.31 is considered Undervalued compared with the five-year average of -4.58. The fair price of MDxHealth SA (MDXH) is between 51.37 to 55.01 according to relative valuation methord. Compared to the current price of 3.27 USD , MDxHealth SA is Undervalued By 93.63% .
What is MDxHealth SA (MDXH) fair value?
MDXH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of MDxHealth SA (MDXH) is between 51.37 to 55.01 according to relative valuation methord.
How does MDXH's valuation metrics compare to the industry average?
The average P/S ratio for MDXH's competitors is 88.20, providing a benchmark for relative valuation. MDxHealth SA Corp (MDXH) exhibits a P/S ratio of 1.31, which is -98.52% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for MDxHealth SA (MDXH) as of Jan 09 2026?
As of Jan 09 2026, MDxHealth SA (MDXH) has a P/B ratio of -20.78. This indicates that the market values MDXH at -20.78 times its book value.
What is the current FCF Yield for MDxHealth SA (MDXH) as of Jan 09 2026?
As of Jan 09 2026, MDxHealth SA (MDXH) has a FCF Yield of -4.11%. This means that for every dollar of MDxHealth SA’s market capitalization, the company generates -4.11 cents in free cash flow.
What is the current Forward P/E ratio for MDxHealth SA (MDXH) as of Jan 09 2026?
As of Jan 09 2026, MDxHealth SA (MDXH) has a Forward P/E ratio of -9.12. This means the market is willing to pay $-9.12 for every dollar of MDxHealth SA’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for MDxHealth SA (MDXH) as of Jan 09 2026?
As of Jan 09 2026, MDxHealth SA (MDXH) has a Forward P/S ratio of 1.31. This means the market is valuing MDXH at $1.31 for every dollar of expected revenue over the next 12 months.